1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

07 Oct 2024
Admin
News Article

Halozyme Expands Global Collaboration and License Agreement with Argenx for ENHANZE

Overview

Halozyme Therapeutics, Inc., a biopharmaceutical company, announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to Halozyme's ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery. argenx, a global immunology company, now has exclusively licensed ENHANZE for a total of six targets, including for the neonatal Fc receptor (FcRn) target.

VYVGART Hytrulo

VYVGART Hytrulo, argenx's branded FcRn blocker, is approved by the US Food and Drug Administration for chronic inflammatory demyelinating polyneuropathy and generalized myasthenia gravis, with additional approvals granted in >25 countries globally for the latter indication.

Terms of Agreement

Under the terms of the expanded exclusive agreement, argenx will make upfront payments of $7.5 million per target nomination for a total of $30 million to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment of up to $85 million per nominated target.
The royalty rate for all products under the agreement is a tiered mid-single digit rate based on annual net sales until expiration of Halozyme's ENHANZE related patents, when the rate will be reduced in one or more steps.
Royalties will be paid for the longer of 10 years from the first commercial sale or until the expiration of the last valid claim of a co-formulation patent.

Statement from the CEO: Halozyme

"We are very pleased to strengthen our relationship with argenx, an innovative leader in immunology dedicated to improving the lives of people suffering from severe autoimmune diseases. We share argenx's patient centric mission and are united in our commitment to improve the lives of patients. As the leader in rapid subcutaneous drug delivery, ENHANZE has clinically demonstrated shorter administration time, offering patients and healthcare practitioners with more convenience and flexibility in how therapies are delivered," said Dr. Helen Torley, president and chief executive officer.
"With the strong proven success of ENHANZE, we look forward to further supporting argenx's momentum as they expand their immunology pipeline with subcutaneous delivery of therapeutics to achieve their Vision 2030."

Statement from the CEO: Argenx

Tim Van Hauwermeiren, chief executive officer of argenx, added, ""We are very excited to have access to Halozyme's leading subcutaneous delivery technology now for six different targets. The expansion of our exclusive access to ENHANZE plays a critical role in solidifying our leadership position and delivering on our commitment to providing life-changing immunology solutions to patients.""

About the Company: Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!